Combining liquid biopsy technologies may help improve tumour monitoring
Results from two studies suggest that this approach is essential to refining liquid biopsy use in early cancer detection and to check tumour progression
Should cancer therapy be tailored based on receptor tyrosine kinase alterations?
Data from a molecular analysis of receptor tyrosine kinase-mutated cancers show a wide heterogeneity of alterations and response to tyrosine kinase inhibitor monotherapy
Dynamic immunoediting of tumours may hold the clue to effective treatment with immunotherapy
Success of immunotherapy is tied to tumour evolution from early- to late-stages, as a study in non-small-cell lung cancer highlights
Molecular cancer early detection and prevention - an attainable goal?
Adoption of molecular-based early detection techniques in clinical practice depends on the success of large-scale clinical studies and cost barriers
Improving the efficacy of engineered T-cells – from gene transfer to genome editing
A new level of sophistication, namely genome editing, is now available to help overcome previous hurdles with adoptive T-cell therapies
New targets for off-the-shelf treatments open up the field of precision immunotherapy
The identification of mutation-derived neoantigens may help elicit antitumour immune responses in patients with cancer, but this approach is challenging
Antibody–drug conjugates show potential in advanced solid tumours
Study data report promising responses and safety profiles in patients with heavily pre-treated malignancies
Can new routes of administration have a place in the application of immunotherapy?
Immunotherapy typically requires intravenous administration, but this may not be the optimal or preferred route for all patients
New therapies, new toxicities
Side-effects may occur at unpredictable timepoints during a patient’s treatment journey and even after treatment cessation
Adjuvant immunotherapy does not improve disease-free survival in renal cell carcinoma
IMmotion010, CheckMate 914 and PROSPER miss their primary endpoints: back to square one for adjuvant immunotherapy?